Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.70 |
| ▸ | ESR1 | P03372 | 15/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27074895 | 1.00 | ESR2 (0.70) | ESR2ESR1HSP90AA1HSD17B1HSD17B2 | |
| SCHEMBL3924959 | 0.82 | ESR1 (1.00) | ESR2ESR1HSP90AA1 | |
| SCHEMBL25341436 | 0.80 | ESR1 (0.59) | ESR2ESR1HSP90AA1 | |
| SCHEMBL29509843 | 0.80 | ESR1 (0.59) | ESR2ESR1HSP90AA1 | |
| SCHEMBL29490953 | 0.75 | FGFR1 (0.51) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL25337719 | 0.75 | FGFR1 (0.51) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL3935295 | 0.74 | ESR1 (1.00) | ESR2ESR1HSP90AA1 | |
| SCHEMBL30791803 | 0.72 | HSD17B1 (0.45) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL27169843 | 0.72 | HSD17B1 (0.45) | ESR2ESR1HSD17B1HSD17B2 | |
| SCHEMBL30791789 | 0.72 | ESR1 (0.70) | ESR2ESR1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | ESR2 484/4885ESR1 1569/4885HSP90AA1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.